Microchip implanted in liver tumors could personalize cancer treatment

NCT ID NCT07193862

Recruiting now Knowledge-focused Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a small implantable device placed directly into liver tumors from colorectal cancer. The device releases tiny amounts of several chemotherapy and immunotherapy drugs to see how the tumor responds. After a few days, the device is removed along with the tumor during planned surgery. The goal is to check if the procedure is safe and can help guide future treatment choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: implantable microdevice containing chemotherapy and immunotherapy drugs (doxorubicin, FOLFOX, botensilimab, balstilimab, bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373)
What this could lead to: If successful, this approach could help doctors choose the most effective drugs for each patient's liver tumors before surgery.
What could go wrong: This is a very early safety study with only 10 participants, so it cannot yet prove the device improves treatment outcomes. The device itself could cause complications or fail to provide useful information.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER METASTATIC

Contacts and locations

Locations

Long Island Jewish Medical Center
RECRUITING

New Hyde Park, New York, 11040, United States
RJ Zuckerberg
RECRUITING

Lake Success, New York, 11042, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.